Targeted cancer therapy: the next generation of cancer treatment
TA Baudino - Current drug discovery technologies, 2015 - ingentaconnect.com
Cancer is one of the leading causes of death in the United States along with heart disease.
The hallmark of cancer treatment has been conventional chemotherapy. Chemotherapeutic …
The hallmark of cancer treatment has been conventional chemotherapy. Chemotherapeutic …
[HTML][HTML] Heterogeneous responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations: new …
A Russo, T Franchina, G Ricciardi, A Battaglia… - International Journal of …, 2019 - mdpi.com
Uncommon Epidermal Growth Factor Receptor (EGFR) mutations represent a distinct and
highly heterogeneous subgroup of Non-Small Cell Lung Cancers (NSCLCs), that accounts …
highly heterogeneous subgroup of Non-Small Cell Lung Cancers (NSCLCs), that accounts …
Outcomes of first-generation EGFR-TKIs against non-small-cell lung cancer harboring uncommon EGFR mutations: a post hoc analysis of the BE-POSITIVE study
S Pilotto, A Rossi, T Vavalà, A Follador, M Tiseo… - Clinical Lung Cancer, 2018 - Elsevier
Background Beyond progression after tyrosine kinase inhibitor in EGFR-positive non-small-
cell lung cancer patients (BE-POSITIVE) was the first Italian multicenter observational study …
cell lung cancer patients (BE-POSITIVE) was the first Italian multicenter observational study …
[HTML][HTML] Endostar regulates EMT, migration and invasion of lung cancer cells through the HGF-Met pathway
Y Shen, Q Chen, L Li - Molecular and cellular probes, 2019 - Elsevier
Abstract Aim Though Endostar (ES) could inhibit tumor growth by inhibiting tumor
angiogenesis, other possible mechanisms have been less reported. This study aims to …
angiogenesis, other possible mechanisms have been less reported. This study aims to …
[HTML][HTML] Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation
J Chantharasamee, N Poungvarin, P Danchaivijitr… - BMC cancer, 2019 - Springer
Background Uncommon epidermal growth factor receptor (EGFR)-mutant non-small cell
lung cancer (NSCLC) is a rare subset of NSCLC. The aim of this study was to investigate the …
lung cancer (NSCLC) is a rare subset of NSCLC. The aim of this study was to investigate the …
EGFR mutations in non-small cell lung cancer: an audit from West China Hospital
Y Tang, W Wang, K Zheng, L Jiang, Y Zou… - Expert Review of …, 2016 - Taylor & Francis
Objectives: To discover the incidence and characteristics of EGFR mutations in non-small
cell lung cancer (NSCLC) in a single, large cohort as a part of routine diagnostic …
cell lung cancer (NSCLC) in a single, large cohort as a part of routine diagnostic …
Clinical Characteristics and Survival Outcomes for Non‐Small‐Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Double Mutations
M Peng, YM Weng, HL Liu, GF Yang… - BioMed research …, 2018 - Wiley Online Library
Multiple randomized clinical trials have demonstrated that epidermal growth factor receptor
(EGFR) exon 19 deletion (19Del) and exon 21 L858R mutation (L858R) are highly …
(EGFR) exon 19 deletion (19Del) and exon 21 L858R mutation (L858R) are highly …
[HTML][HTML] Plasma MiRNA alterations between NSCLC patients harboring Del19 and L858R EGFR mutations
Y Ma, P Xu, Y Mi, W Wang, X Pan, X Wu, Q He, H Liu… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Based on recognition of driver mutations, treatment paradigm for non-small-cell lung cancer
(NSCLC) patients has been shifted. However, recently exon 19 deletion mutation (del19) of …
(NSCLC) patients has been shifted. However, recently exon 19 deletion mutation (del19) of …
Loading and sustained release of sodium alginate membranes on pyridirubicin chloride
To develop diversified drug carriers for local treatment of cancer, three types of alginate
membranes were fabricated by spin-coating, freeze drying and electrospinning. The uniaxial …
membranes were fabricated by spin-coating, freeze drying and electrospinning. The uniaxial …
DEVELOPMENT OF ERLOTINIB ENCAPSULATED SELF-ASSEMBLED MIXED MICELLES: OPTIMIZATION AND IN VITRO EVALUATION.
S Patel, A Patel - Indian Drugs, 2023 - search.ebscohost.com
For the treatment of lung cancer, erlotinib is used as primary treatment. Erlotinib is an
epidermal growth factor receptor inhibitor, however it is deposited in normal cells also and …
epidermal growth factor receptor inhibitor, however it is deposited in normal cells also and …